Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PelvEx II trial in locally recurrent rectal cancer
NL-OMON60264Phase 3Recruiting
- Sponsor
- Catharina Ziekenhuis
- Start
- Oct 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin in rectal cancer (2 arms), sponsored by Catharina Ziekenhuis. Primary endpoint: Rate of clear resection margins after surgery. Started Oct 2020; status: recruiting.
02
Drugs
oxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NL-OMON60264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60264.